开云app官网登录入口网页版-官方正版

#无进展生存期#

55篇内容 | 1873人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2219024, encodeId=752122190243c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a> <a href='/topic/show?id=6b0711e64262' target=_blank style='color:#2F92EE;'>#原发灶不明确的癌症#</a> <a href='/topic/show?id=427d11e64343' target=_blank style='color:#2F92EE;'>#分子引导治疗#</a>, objectTitle=近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！, objectType=article, longId=837614, objectId=316883e61476, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539222993_5579292.jpg, objectUrl=/article/show_article.do?id=316883e61476, replyNumber=0, likeNumber=51, createdTime=2024-08-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=316883e61476, moduleTitle=近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=316883e61476)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1459692, encodeId=6c4b145969288, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, objectType=article, longId=728906, objectId=8ed1e2890609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed1e2890609, replyNumber=0, likeNumber=81, createdTime=2022-06-10, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed1e2890609, moduleTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8ed1e2890609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459691, encodeId=b2ef145969182, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=57, createdTime=2022-05-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459690, encodeId=77a1145969006, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=68, createdTime=2022-04-12, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459689, encodeId=6f60145968916, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, objectType=article, longId=293793, objectId=02ce293e9390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce293e9390, replyNumber=0, likeNumber=74, createdTime=2022-01-12, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce293e9390, moduleTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=02ce293e9390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459688, encodeId=d541145968832, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=291938, objectId=b40f29193897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40f29193897, replyNumber=0, likeNumber=74, createdTime=2021-12-17, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40f29193897, moduleTitle=J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b40f29193897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459687, encodeId=cb16145968e65, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=217398, objectId=e57c21e398b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57c21e398b5, replyNumber=0, likeNumber=86, createdTime=2021-09-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57c21e398b5, moduleTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e57c21e398b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459686, encodeId=9743145968641, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, objectType=article, longId=212407, objectId=dc0d21240ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc0d21240ed5, replyNumber=0, likeNumber=0, createdTime=2021-06-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc0d21240ed5, moduleTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dc0d21240ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459685, encodeId=b69d1459685e2, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=86, createdTime=2021-05-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459684, encodeId=b1c014596842d, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, objectType=article, longId=207681, objectId=b94020e681d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94020e681d7, replyNumber=0, likeNumber=73, createdTime=2021-02-28, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94020e681d7, moduleTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b94020e681d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459683, encodeId=709a1459683ff, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, objectType=article, longId=203482, objectId=6ec6203482bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec6203482bb, replyNumber=0, likeNumber=61, createdTime=2020-11-18, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec6203482bb, moduleTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6ec6203482bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459682, encodeId=a94b14596829c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, objectType=article, longId=199750, objectId=6fb7199e501c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb7199e501c, replyNumber=0, likeNumber=74, createdTime=2020-08-22, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb7199e501c, moduleTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6fb7199e501c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459681, encodeId=5997145968158, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=0, createdTime=2020-08-13, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459680, encodeId=cfe11459680ca, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=75, createdTime=2020-08-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459679, encodeId=41aa14596e910, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=70, createdTime=2020-08-06, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=65, createdTime=2019-12-18, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459677, encodeId=1f9f14596e76e, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=48, createdTime=2019-12-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459676, encodeId=844a14596e6b5, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=64, createdTime=2019-10-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459675, encodeId=4aca14596e5d4, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=60, createdTime=2019-09-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459674, encodeId=0f4314596e4dd, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, objectType=article, longId=177361, objectId=414c1e7361c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=414c1e7361c0, replyNumber=0, likeNumber=72, createdTime=2019-08-11, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=414c1e7361c0, moduleTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=414c1e7361c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

无进展生存期

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#无进展生存期# #原发灶不明确的癌症# #分子引导治疗#

近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！

2024-08-07发表于上海

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%

2022-06-10

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响

2022-05-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍

2022-01-12

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-12-17

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-09-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期

2021-06-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-05-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！

2021-02-28

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期

2020-11-18

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期

2020-08-22

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-08-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究

2019-08-11

科室
- - 订阅+
  - 更多科室
工具
服务